First Time Loading...

Mirati Therapeutics Inc
NASDAQ:MRTX

Watchlist Manager
Mirati Therapeutics Inc Logo
Mirati Therapeutics Inc
NASDAQ:MRTX
Watchlist
Price: 58.7 USD
Updated: Apr 29, 2024

Mirati Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mirati Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Mirati Therapeutics Inc
NASDAQ:MRTX
Net Income (Common)
-$725.9m
CAGR 3-Years
-30%
CAGR 5-Years
-52%
CAGR 10-Years
-31%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$5.7B
CAGR 3-Years
258%
CAGR 5-Years
1%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$6.7B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
25%

See Also

What is Mirati Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-725.9m USD

Based on the financial report for Sep 30, 2023, Mirati Therapeutics Inc's Net Income (Common) amounts to -725.9m USD.

What is Mirati Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-31%

Over the last year, the Net Income (Common) growth was 2%. The average annual Net Income (Common) growth rates for Mirati Therapeutics Inc have been -30% over the past three years , -52% over the past five years , and -31% over the past ten years .